Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0941 add-on to insulin in T2DM
NCT00824616Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2009
- Primary completion
- May 2010
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing MK-0941 with Placebo (2 arms). Primary endpoints: Change From Baseline in Hemoglobin A1c at 20 weeks and Number of Participants Who Experienced One or More Episodes of Hypoglycemia at 20 weeks. Started Jan 2009; status: completed.
02
Drugs
mk-0941
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00824616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00824616.